Our Technology

Our lead drug product candidate utilizes our sustained-release micro-suspension technology that is designed to meet the specific and unique needs of epidural administration for the treatment of sciatica.

Back pain is the leading cause of disability in the United States and globally.  $135 billion is spent annual in the United States on the treatment of neck and back pain, more than any other condition. [1]

Key Features

Feature Image
Sustained-release profile potentially provides longer term pain relief from single injection
Feature Image
Potentially minimizes the need to perform repeat injections
Feature Image
Designed to address the safety requirements unique to epidural route of administration
Feature Image
Will utilize the same injection procedure as current therapies
Feature Image
Utilizes a potent, well-established, anti-inflammatory steroid active ingredient
Feature Image
In development for FDA approval to offer physicians an 'on-label' drug option

Back Pain

Millions of back pain patients receive 10-12 million epidural steroid injections (ESIs) every year for back pain. [2,3]
A herniated disc is the most common cause of this type of back pain.
The injection is usually performed in a fluoroscopy suite to verify placement of the needle in the epidural tissue just outside the spinal cord. A significant portion of ESIs are repeat injections (a 2nd, 3rd, or 4th injection) over the first few months of treatment. Elimination of these repeat ESIs would drastically reduce the number of injection procedures that are performed, reduce procedure related infections and complications, and aid in the management of overall treatment costs. There is a documented risk of paralysis with transforaminal epidural injections of water insoluble generic steroids, which has been communicated by the FDA in 2014. [4]
There is no FDA approved steroid for epidural injection to treat back pain. All ESI's are performed 'off-label'.
Back Pain Image
(1) Dieleman, J. L. et al. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA 323, 863–884 (2020). (2) Manchikanti, Laxmaiah, Mark V. Boswell, Sukdeb Datta, Bert Fellows, Salahadin Abdi, Vijay Singh, Ramsin M. Benyamin, et al. 2009. “Comprehensive Review of Therapeutic Interventions in Managing Chronic Spinal Pain.” Pain Physician 12 (4): E123-198. (3) Abbott, Zach I., Kavita V. Nair, Richard R. Allen, and Venu R. Akuthota. 2012. “Utilization Characteristics of Spinal Interventions.” The Spine Journal: Official Journal of the North American Spine Society 12 (1): 35–43. (4) Racoosin, Judith A., Sally M. Seymour, Laurelle Cascio, and Rajdeep Gill. 2015. “Serious Neurologic Events after Epidural Glucocorticoid Injection — The FDA’s Risk Assessment.” New England Journal of Medicine